ClinicalTrials.gg
RecruitingNCT06932237PASCUpdated Mar 31, 2026

Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans

An observational study in Neuro-PASC and Long COVID, sponsored by VA Office of Research and Development. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by VA Office of Research and Development · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · VA Office of Research and Development.

Started
2025
with 1 other
Observational
3 of 11
3 open now
Registered
11th of 11
by date

Among the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 11th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

8 of the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, or all of them as a file.
02

Study summary

Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) assess and monitor cognitive function and psychiatric symptoms in Veterans post-COVID; 2) evaluate biomarkers of inflammation and signaling pathways associated with viral infection and neuropsychiatric function; and 3) integrate neuropsychiatric and neurological findings with biological data to identify biomarkers and clinical endpoints associated with disease progression or severity, as well as those for promoting brain repair and attenuating those symptoms.

Read the detailed description

The goal of this research project is to identify the neuroinflammatory mechanisms contributing to post-COVID cognitive deficits and neuropsychiatric symptoms [neuro-PASC (post-acute sequelae of SARS CoV-2 infection)]. This collaborative research effort will also characterize new or worsened mental health symptoms and genetic and environmental risk factors for the incidence and severity of post-COVID neuropsychiatric impairments. Aim 1 will monitor and evaluate cognitive injury and neuro-PASC symptoms and determine whether APOE genotype modulates severity of the cognitive injury and neuro-PASC symptoms. Cognitive functioning will be evaluated over time using neuropsychological measures assessing domains most relevant to PASC: learning and memory, attention/concentration, social cognition/emotions, and executive function; assessments will include standardized measures. Mental health symptoms known to be induced and exacerbated by inflammation and potentially developing as a result of COVID-19 will also be evaluated. APOE genotyping will be determined based on saliva or blood samples. Aim 2 will identify immune-related biomarkers associated with cognitive injury and neuro-PASC symptoms. Blood (plasma and cells) will be used to identify biomarkers associated with PASC progression or severity, promotion of brain repair, attenuation of symptoms. Plasma will be used for Olink proteomics, followed by confirmatory multiplex assays or enzyme-linked immunosorbent assays (ELISAs). The investigators will assess relationships among biomarkers and cognitive injury and neuro-PASC symptoms across APOE genotypes and contribute data and samples to the repository managed by Dr. Moorman (Co-Investigator). Aim 3 (exploratory aim; conducted in Portland only) will assess neuroimaging correlates of cognitive injury and neuro-PASC symptoms. Neuroimaging evaluations (i.e., whole brain voxel-based morphometry, diffusion-tensor imaging, resting-state connectivity, and task-based assessments) will be conducted at baseline and at 12 months to correlate magnetic resonance imaging (MRI) measures with symptoms of long COVID (e.g., cognitive impairment and neuropsychiatric symptoms) across APOE genotypes.

03

Conditions studied

  • Neuro-PASC
  • Long COVID

Keywords

  • COVID-19
  • Veterans
  • Cognitive
  • Post-Acute COVID-19 Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Veterans

Eligibility criteria

Inclusion Criteria:

Eligible participants will:

  • have a history of SARS-CoV-2 infection 4 weeks prior to enrollment, defined as a positive PCR or home antigen test
  • be able to give as determined by brief cognitive exam and evaluation of understanding of the risks, benefits, and voluntary nature of the study

Additionally, participants enrolled as part of the neuro-PASC group must also:

  • currently experience neuro-PASC symptoms, not present prior to infection, as confirmed by the "Long COVID-19 Symptom Assessment" scale, a self-report measure that consists of 46 common COVID-19 sequela symptoms

Exclusion Criteria:

Exclusion criteria for all groups:

  • diagnosed with dementia, traumatic brain injury, a neurological syndrome (e.g. Parkinson disease, Alzheimer disease), or other progressive cognitive disorder before SARS-CoV-2 infection
  • diagnosed with a mood or psychotic disorder before SARS-CoV-2 infection
  • history of fibromyalgia or chronic fatigue syndrome prior to SARS-CoV-2 infection
  • unstable medical conditions or active uncontrolled or inflammatory conditions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Neuro-PASC

    All participants enrolled in the study will attend 4 study visits: 1) Screening, 2) Baseline, 3) 6-Month Follow-up, and 4) 12-Month Follow-up. At the Baseline, 6-Month, and 12-Month follow-up, participants will complete an online neuropsychological assessment, questionnaires, blood draw, and saliva collection

  • Neuro-PASC-imaging

    A subset (60) of Portland VA only participants will be provided with the opportunity to complete an MRI visit at baseline and the 12-month follow-up.

06

What researchers measure

Primary outcomes

  1. Fatigue Severity Scale (FSS)

    A nine-item self-report questionnaire designed to assess fatigue as a symptom of a variety of different chronic conditions and disorders.

    Time frame: Baseline, 6-Month, 12-Month

  2. Prospective and Retrospective Memory Questionnaire (PRMQ)

    A self-report measure of everyday memory, assessing prospective (the ability to remember to do things in the future) and retrospective memory.

    Time frame: Baseline, 6-Month, 12-Month

  3. Spatial Working Memory (SWM)

    Online cognitive assessment requiring retention and manipulation of visuospatial information; measures executive functioning (i.e., strategy) and working memory.

    Time frame: Baseline, 6-Months, 12-Months

  4. Paired Associates Learning (PAL)

    Online cognitive assessment measuring visual memory and new learning.

    Time frame: Baseline, 6-Month, 12-Month

  5. Stockings of Cambridge (SOC)

    Online cognitive assessment measuring problem-solving strategies.

    Time frame: Baseline, 6-Month, 12-Month

  6. Delayed Matching Sample (DMS)

    Online cognitive assessment measuring visual matching ability and short-term visual recognition memory.

    Time frame: Baseline, 6-Month, 12-Month

  7. Rapid Visual Information Processing (RVP)

    Online cognitive assessment measuring sustained attention.

    Time frame: Baseline, 6-Month, 12-Month

  8. Apolipoprotein E (APOE) Genotyping

    A genetic test that determines a person's inherited variations in the APOE gene. This gene plays a role in cholesterol metabolism and brain health. Blood and saliva samples will be used.

    Time frame: Baseline, 6-Months, 12-Months

  9. Long Covid Questionnaire

    Self-report measure that assesses the continued presence of Long-COVID symptomology.

    Time frame: Baseline

  10. Delis-Kaplan Executive Functioning - Verbal Fluency (D-KEFS-VF)

    Neuropsychological assessment measure of verbal behavioral productivity and cognitive flexibility.

    Time frame: Baseline, 6-Months, 12-Months

Secondary outcomes

  1. Posttraumatic Stress Disorder Checklist - Civilian Version (PCL-C)

    A standardized self-report rating scale for PTSD comprising 17 items that correspond to the key symptoms of PTSD.

    Time frame: Baseline, 6-Month, 12-Month

  2. Patient Health Questionnaire-9 (PHQ-9)

    Self-report questionnaire objectifying and assessing degree of depression severity.

    Time frame: Baseline, 6-Months, 12-Months

  3. Generalized Anxiety Disorder-7 (GAD-7)

    A self-reported questionnaire used to assess the severity of anxiety symptoms.

    Time frame: Baseline, 6-Month, 12-Month

  4. Biomarkers

    Obtained from collected blood samples and saliva, biomarkers (including viral variants, genetic susceptibility, inflammatory markers, diagnostic markers, etc.) associated with specific symptoms of post-COVID conditions will be identified.

    Time frame: Baseline, 6-Months, 12-Months

Other outcomes

  1. Neuroimaging

    To detect pathological and restorative changes in the brain of COVID-19 survivors, neuroimaging evaluations will correlate magnetic resonance imaging (MRI) measures with symptoms of neuro-PASC.

    Time frame: Baseline, 12-Months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 37 months after the start.

Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 37 months is above that.

Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 17, 2025
StartActual
Feb 20, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06932237
Collaborators
James H. Quillen Department of Veterans Affairs Medical Center
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Feb 20, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Mar 31, 2026

Study contacts

Jennifer M Loftis, MA PhD
Contact
Jennifer.Loftis2@va.gov
(503) 220-8262 ext. 57155
Emily R Sano, MA
Contact
emily.sano@va.gov
(503) 220-8262 ext. 58290
Jennifer M Loftis, MA PhD
principal investigator · VA Portland Health Care System, Portland, OR

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion